Other agents, such as FHD-609 and FHD-286, which act as BRD9 degraders and BRG1 inhibitors, respectively, have shown a promising increase in survival rate after 35 days of continuous treatment in the same SCLC-P xenografts (Duplaquet et al., 2024). This evidence concerns the gene BRD9 and small cell lung carcinoma.